NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
For individuals who prefer a prescription pathway, these remain the approved options at this time
Lee SH, Ko HM, Jee W, Kim H, Chung WS, Jang HJ
If you are considering Semaglutide GLP-1 as part of your weight loss strategy, we invite you to discuss your options with our skilled healthcare team, who are ready to guide you every step of the way
.webp)
